SIGASIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox d…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 SIGA (SIGA) Q2 2026 Earnings Call Transcript Revenue fell 49% year-over-year as government contract deliveries slowed. | ||
 SIGA Technologies, Inc. Q2 2026 Earnings Call Summary Moby summary of SIGA Technologies, Inc.'s Q2 2026 earnings call | ||
 Siga Technologies Q2 Earnings Call Highlights Siga Technologies (NASDAQ:SIGA) reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of | ||
SIGA Technologies Inc (SIGA) (Q2 2026) Earnings Call Highlights: Strong Revenue and Strategic ... SIGA reports $38 million in product revenues, driven by US stockpile deliveries and international growth, while navigating slower-than-expected US procurement timelines. | ||